ArticleTherapeutic advances in medical oncology2020

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median.

Andrea Messori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.